European Innovation Council

PrecisionLife is a company focused on advancing precision medicine by leveraging its proprietary artificial intelligence platform to enhance the understanding of chronic diseases. It specializes in patient stratification, which allows for the identification of novel subgroups within patient populations, thereby generating insights that inform the discovery of new drug targets and drug repositioning candidates. By utilizing unique and patentable biomarkers, PrecisionLife connects patients with specific disease sub-groups and potential therapies, ultimately aiming to create personalized treatment alternatives. The company’s innovative approach not only drives advancements in biopharmaceuticals but also seeks to improve patient outcomes, enabling individuals to lead longer and healthier lives.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable knowledge for various sectors including academic research, plant and animal breeding, and biomedicine. Sequentia serves a diverse client base of over 30 public and private research centers, companies, and hospitals, participating in more than 160 R&D projects. The company offers cloud software, custom software, and bioinformatics consulting services, with notable contributions such as two open-source biodata banks and an award-winning R&D line called Tricopharming, established in 2014. Sanseverino and Aiese have published over 40 scientific articles in high-impact journals, underscoring the company's expertise in omics sciences.

Genomika Lietuva is a business that provides cutting-edge, perceptive, and meticulously optimized solutions for the biomedical sciences. It creates DNA storage technologies that allow for high-density storage of significant amounts of information in a remarkably tiny area.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

VIVAN Therapeutics is a company focused on developing personalized cancer therapeutics aimed at revolutionizing cancer care. Utilizing a novel assay technology licensed from the Center for Personalized Cancer Therapeutics at Mt Sinai New York, VIVAN offers a comprehensive genomics-based drug screening service that integrates blockchain technology. The company's approach includes the Personal Discovery Process (PDP), which treats each patient as a unique case by engineering their tumor's genetic complexity into a model using fruit flies, allowing for the evaluation of both FDA-approved cancer and non-cancer drugs. This innovative strategy aims to provide less toxic and more affordable treatment options, enhancing the effectiveness of cancer care through tailored recommendations and the development of new diagnostics and decision support tools.

Enduro Genetics is a technology provider that specializes in enhancing large-scale fermentations through its proprietary synthetic biology technology. The company focuses on improving the performance of fermentation processes by developing a genetic plugin technology that is free of antibiotic resistance genes. This innovation allows for higher yields by enriching spontaneous high producers within the fermentation population, facilitating the production of complex or cellular inhibit products by addressing strain instability. By maximizing the performance of cells derived from production strains, Enduro aims to bolster the competitiveness of both current and future green bioproduction initiatives.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

Core Biogenesis is a biotechnology company based in Paris, France, founded in 2020. It specializes in developing next-generation recombinant protein production technologies that utilize proprietary gene editing and plant biotechnology. The company aims to significantly lower the cost of producing growth factors, which are essential molecules used in the clean meat and cell therapy industries. Core Biogenesis employs an ultra-scalable bioproduction as a service (UBaaS) platform, allowing for the efficient mass production of valuable bioproducts by using plants as biofactories. This innovative approach enhances the speed and scalability of molecule extraction while enabling clients in the healthcare sector to improve cell growth, division, and survival, ultimately increasing yields and reducing costs.

Genetika+ is a medical platform focused on personalizing treatment for depression by utilizing advanced biological, medical, and genetic data. The company has developed an innovative testing tool that predicts the most effective drug therapy for individual patients, thus enabling faster treatment solutions with reduced side effects and lower dosing requirements. By employing a combination of stem-cell technology, genomics, and artificial intelligence, Genetika+ aims to optimize treatment while also aiding pharmaceutical companies in enhancing their product offerings and streamlining clinical trials. This approach not only tailors treatments to specific patient needs but also seeks to advance care for psychiatric and neurological conditions.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Core Biogenesis is a biotechnology company based in Paris, France, founded in 2020. It specializes in developing next-generation recombinant protein production technologies that utilize proprietary gene editing and plant biotechnology. The company aims to significantly lower the cost of producing growth factors, which are essential molecules used in the clean meat and cell therapy industries. Core Biogenesis employs an ultra-scalable bioproduction as a service (UBaaS) platform, allowing for the efficient mass production of valuable bioproducts by using plants as biofactories. This innovative approach enhances the speed and scalability of molecule extraction while enabling clients in the healthcare sector to improve cell growth, division, and survival, ultimately increasing yields and reducing costs.

Computomics GmbH is a bioinformatics company based in Tübingen, Germany, specializing in molecular data analysis for crop biotechnology and agricultural research. Founded in 2012, the company employs advanced artificial intelligence and machine learning techniques to provide a range of services, including genome assembly, transcriptome studies, and genomic selection. Computomics focuses on analyzing complex plant genomes, offering solutions such as differential gene expression analysis, reference-free genotyping, and DNA methylation analysis. Its interactive visualization tools empower researchers to make data-driven decisions while ensuring thorough analysis and comprehensive reporting of genomic data. With a diverse team of experts in machine learning, biology, and bioinformatics, Computomics has successfully completed over 190 projects, facilitating sustainable agricultural development and aiding in the advancement of global food security.

Core Biogenesis is a biotechnology company based in Paris, France, founded in 2020. It specializes in developing next-generation recombinant protein production technologies that utilize proprietary gene editing and plant biotechnology. The company aims to significantly lower the cost of producing growth factors, which are essential molecules used in the clean meat and cell therapy industries. Core Biogenesis employs an ultra-scalable bioproduction as a service (UBaaS) platform, allowing for the efficient mass production of valuable bioproducts by using plants as biofactories. This innovative approach enhances the speed and scalability of molecule extraction while enabling clients in the healthcare sector to improve cell growth, division, and survival, ultimately increasing yields and reducing costs.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Computomics GmbH is a bioinformatics company based in Tübingen, Germany, specializing in molecular data analysis for crop biotechnology and agricultural research. Founded in 2012, the company employs advanced artificial intelligence and machine learning techniques to provide a range of services, including genome assembly, transcriptome studies, and genomic selection. Computomics focuses on analyzing complex plant genomes, offering solutions such as differential gene expression analysis, reference-free genotyping, and DNA methylation analysis. Its interactive visualization tools empower researchers to make data-driven decisions while ensuring thorough analysis and comprehensive reporting of genomic data. With a diverse team of experts in machine learning, biology, and bioinformatics, Computomics has successfully completed over 190 projects, facilitating sustainable agricultural development and aiding in the advancement of global food security.

enGenome is a bioinformatics company focused on enhancing the diagnosis and treatment of genetic diseases through its advanced genomic interpretation and bioinformatics software. By automating variant interpretation guidelines, the company reduces the occurrence of variants of uncertain significance and provides comprehensive reports that include supporting evidence. This technology enables geneticists to accurately and swiftly identify pathogenic genomic variants, ultimately leading to improved patient outcomes. Through its omics-based reporting, enGenome aims to assist physicians in making informed decisions regarding diagnosis and therapies, thereby contributing to more effective healthcare solutions.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable knowledge for various sectors including academic research, plant and animal breeding, and biomedicine. Sequentia serves a diverse client base of over 30 public and private research centers, companies, and hospitals, participating in more than 160 R&D projects. The company offers cloud software, custom software, and bioinformatics consulting services, with notable contributions such as two open-source biodata banks and an award-winning R&D line called Tricopharming, established in 2014. Sanseverino and Aiese have published over 40 scientific articles in high-impact journals, underscoring the company's expertise in omics sciences.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable knowledge for various sectors including academic research, plant and animal breeding, and biomedicine. Sequentia serves a diverse client base of over 30 public and private research centers, companies, and hospitals, participating in more than 160 R&D projects. The company offers cloud software, custom software, and bioinformatics consulting services, with notable contributions such as two open-source biodata banks and an award-winning R&D line called Tricopharming, established in 2014. Sanseverino and Aiese have published over 40 scientific articles in high-impact journals, underscoring the company's expertise in omics sciences.

Genome Biologics is a biotherapeutics company focused on the discovery of therapeutic targets and the development of RNA-targeted therapies, particularly for cardiovascular and cardiometabolic diseases. The company utilizes advanced technology platforms that combine AI-based machine learning with innovative single-cell in vitro and in vivo transgenesis approaches. This integration allows Genome Biologics to identify new therapeutic compounds and repurpose existing ones effectively. By streamlining the drug development process, the company aims to reduce the cost, time, and ethical challenges associated with preclinical research, ultimately facilitating the development of effective treatments for diseases that currently lack viable options.

Developer of a microbiome analysis technology designed to monitor the microbiome status and function, and quantify its impact on all aspects of human life. The company offers a benchtop device and microbiome profiling services using optical mapping-based technology, enabling researchers and clinicians to perform strain-level microbiome analysis with high sensitivity, specificity, and reproducibility.

Developer of a microbiome analysis technology designed to monitor the microbiome status and function, and quantify its impact on all aspects of human life. The company offers a benchtop device and microbiome profiling services using optical mapping-based technology, enabling researchers and clinicians to perform strain-level microbiome analysis with high sensitivity, specificity, and reproducibility.